Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2Sarcoma 1

Conditions

Venous Thromboembolism 4Venous Thrombosis 3Neoplasms 3Thromboembolism 2Pulmonary Embolism 2Ovarian Neoplasms 2Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Thrombosis 1Sarcoma 1Postoperative Complications 1Lung Neoplasms 1Fallopian Tube Neoplasms 1Esophageal Neoplasms 1Endometrial Neoplasms 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Paclitaxel 328Carboplatin 323Bevacizumab 171Gemcitabine 106liposomal doxorubicin 104pembrolizumab 101Cyclophosphamide 96Topotecan 94olaparib 92Cisplatin 92niraparib 69Docetaxel 57Taxes 52Doxorubicin 51Drug Therapy 45fludarabine 40Filgrastim 39Nivolumab 37Magnetic Resonance Spectroscopy 34Surveys and Questionnaires 33Specimen Handling 33Etoposide 32Hyperthermic Intraperitoneal Chemotherapy 31Blood Specimen Collection 29Immunoglobulin G 27Disulfides 27Peripheral Blood Stem Cell Transplantation 26Cytoreduction Surgical Procedures 25Albumin-Bound Paclitaxel 25durvalumab 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Ovarian Neoplasms × Fondaparinux × Clear all
NCT00381888 2017-12-28

Fondaparinux in Preventing Blood Clots in Patients Undergoing Surgery for Gynecologic Cancer

Masonic Cancer Center, University of Minnesota

Phase 2 Completed
44 enrolled 7 charts
GynecologicSarcoma

Carcinoma, Ovarian Epithelial, Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Sarcoma, Thromboembolism, Vaginal Neoplasms, Vulvar Neoplasms, Endometrial Neoplasms

NCT00659399 2015-03-18

Feasibility Study of Short Term Fondaparinux (Arixtra) in Chemotherapy-Pretreated Ovarian Carcinoma Patients at High Risk of Progression

NYU Langone Health

Phase 1 Withdrawn
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡